SRPTSarepta Therapeutics, Inc.

SRPT Stock Price, Valuation & Chart | Sarepta Therapeutics, Inc.

Compare

$23.210+1.88 (+8.81%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology SRPT intrinsic value SRPT calculated fair value vs price

Overview Financials Dividends Ratios

SRPT Historical price chart

SRPT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.45B

PE Ratio-38.68

EPS-0.6

Trading Volume4.80M

Today's High/Low23.61/21.33

Dividend Yield0.00

52 Week High/Low25.32/14.68

Shares Outstanding105.58M

SRPT Financial Statement

SRPT Analyst ratings

SRPT Analysis & performance metrics

SRPT Company profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other…

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is…

SRPT Management team

Name

Position

Louise R. Rodino-Klapac Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Research & Development

Dallan Murray

Executive Vice President & Chief Customer Officer

Cristin L. Rothfuss J.D.

Executive Vice President, Chief General Counsel & Corporate Secretary

Diane L. Berry Ph.D.

Executive Vice President and Chief of Global Policy & Advocacy Officer

Francesca T. NolanCTO

Executive Director of Investor Relations and Corporate Communications

Ian Michael EstepanCFO

Executive Vice President & Chief Financial Officer

Bilal Arif

Executive Vice President & Chief Technical Operations Officer

Douglas S. Ingram Esq.CEO

President, Chief Executive Officer & Director

Name

Position

Louise R. Rodino-Klapac Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Research & Development

Dallan Murray

Executive Vice President & Chief Customer Officer

Cristin L. Rothfuss J.D.

Executive Vice President, Chief General Counsel & Corporate Secretary

Diane L. Berry Ph.D.

Executive Vice President and Chief of Global Policy & Advocacy Officer

Francesca T. NolanCTO

Executive Director of Investor Relations and Corporate Communications

Ian Michael EstepanCFO

Executive Vice President & Chief Financial Officer

Bilal Arif

Executive Vice President & Chief Technical Operations Officer

Douglas S. Ingram Esq.CEO

President, Chief Executive Officer & Director

Management Team

Louise R. Rodino-Klapac Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Research & Development

Dallan Murray

Executive Vice President & Chief Customer Officer

Cristin L. Rothfuss J.D.

Executive Vice President, Chief General Counsel & Corporate Secretary

Diane L. Berry Ph.D.

Executive Vice President and Chief of Global Policy & Advocacy Officer

Francesca T. NolanCTO

Executive Director of Investor Relations and Corporate Communications

Ian Michael EstepanCFO

Executive Vice President & Chief Financial Officer

Bilal Arif

Executive Vice President & Chief Technical Operations Officer

Douglas S. Ingram Esq.CEO

President, Chief Executive Officer & Director

Management

Louise R. Rodino-Klapac Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Research & Development

Dallan Murray

Executive Vice President & Chief Customer Officer

Cristin L. Rothfuss J.D.

Executive Vice President, Chief General Counsel & Corporate Secretary

Diane L. Berry Ph.D.

Executive Vice President and Chief of Global Policy & Advocacy Officer

Francesca T. NolanCTO

Executive Director of Investor Relations and Corporate Communications

Ian Michael EstepanCFO

Executive Vice President & Chief Financial Officer

Bilal Arif

Executive Vice President & Chief Technical Operations Officer

Douglas S. Ingram Esq.CEO

President, Chief Executive Officer & Director

Total 8 executives

SRPT Frequently asked questions

What is Sarepta Therapeutics, Inc. (SRPT) Stock Price?

Current stock price of Sarepta Therapeutics, Inc. (SRPT) stock is $23.210. The stock price is +8.81% higher in the session. The intraday range can be seen from this page. Volume of Sarepta Therapeutics, Inc. (SRPT) stock is 4.80M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Sarepta Therapeutics, Inc. (SRPT) stock price going up or down today?

The stock price of Sarepta Therapeutics, Inc. (SRPT) can change with earnings, company news, and overall market sentiment. Sarepta Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Sarepta Therapeutics, Inc. stock expensive at its current price?

Whether Sarepta Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for SRPT on this page is -38.68. EPS on this page is -0.60. Compare those figures with peers and growth expectations before deciding if the current Sarepta Therapeutics, Inc. price is justified.

How has the stock price of Sarepta Therapeutics, Inc. (SRPT) performed historically?

Historical performance for Sarepta Therapeutics, Inc. (SRPT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how SRPT reacted to past earnings and market events.

Should I buy Sarepta Therapeutics, Inc. (SRPT) stock, at this price?

Buying Sarepta Therapeutics, Inc. (SRPT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.